Literature DB >> 12786605

Review article: diagnosis, monitoring and treatment of distal colitis.

M Vecchi1, S Saibeni, M Devani, E Rondonotti, R De Franchis.   

Abstract

The diagnostic work-up of ulcerative colitis at presentation is based on the collection of clinical, microbiological, radiological, endoscopic and histologic data. Serological markers are characterized by too low a sensitivity to be commonly utilized in clinical practice. Although endoscopic and histologic features are characterized by very high sensitivity and specificity for the diagnosis of ulcerative colitis, negative stool cultures and parasites are mandatory to exclude an infectious aetiology at presentation. The treatment of choice of an acute flare-up of distal ulcerative colitis is represented by oral or topical mesalazine, or a combination of both, whereas the use of topical or systemic steroids should be restricted to patients who prove to be refractory to first-line treatments. Preliminary data suggest that the achievement of endoscopic and histologic remission after an acute flare of the disease might be associated with a prolonged remission.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12786605     DOI: 10.1046/j.1365-2036.17.s2.3.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

Review 1.  Emerging drugs for the treatment of ulcerative colitis.

Authors:  Luca Pastorelli; Theresa T Pizarro; Fabio Cominelli; Maurizio Vecchi
Journal:  Expert Opin Emerg Drugs       Date:  2009-09       Impact factor: 4.191

Review 2.  MMX® technology and its applications in gastrointestinal diseases.

Authors:  Silvia Nardelli; Laura Francesca Pisani; Gian Eugenio Tontini; Maurizio Vecchi; Luca Pastorelli
Journal:  Therap Adv Gastroenterol       Date:  2017-05-25       Impact factor: 4.409

3.  Comparison of the healing effects of mesazaline and Ganoderma lucidum in acetic acid-induced colitis in rats.

Authors:  Hüseyin Özden; Yaşar Şahin; Asuman Kilitçi; Gökhan Karaca; Muhammed Gömeç; Ahmet Yildiz; Cahit Uçar
Journal:  Ann Surg Treat Res       Date:  2022-01-03       Impact factor: 1.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.